In Depth 31 Oct 2025 Spooky science: lab-grown breakthroughs or nightmares? From growing mini-organs to reviving the dodo and gene-editing embryos, boundaries between sci-fi and today’s advances are dissolving fast. October 31, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 29 Oct 2025 Parkinson’s disease: biotech’s pursuit for more therapies Rigorous research aims to boost therapeutic options for people with Parkinson’s disease. What do biotechs have in store? October 29, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 22 Oct 2025 PCSK9’s second act: From antibodies to gene editing With Eli Lilly’s recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents. October 22, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 17 Oct 2025 NLS Days: How do things look for biotech in Sweden? As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden. October 17, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 15 Oct 2025 The advent of AI for peptide design: An emerging field Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for peptides? October 15, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 14 Oct 2025 Prader Willi syndrome: five much-anticipated therapies poised for approval The treatment drug to address insatiable hunger in people with Prader-Willi syndrome was greenlit this year. Discover five therapies in line for approval. October 14, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 13 Oct 2025 Cambridge’s biotech scene: The cornerstone of the UK’s Golden Triangle Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge’s biotech scene so special. October 13, 2025 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 7 Oct 2025 AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS). October 7, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 3 Oct 2025 The biggest biotech funding rounds in September 2025 uniQure, Dianthus Therapeutics, and Mineralys Therapeutics bagged the biggest biotech funding rounds overall in September 2025. October 3, 2025 - 5 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 26 Sep 2025 Can biotechnology reduce animal testing in medicine? Animal testing is crucial for measuring the efficacy and safety of new treatments. It is also a step that everyone would like to avoid as much as possible for economic, regulatory, and ethical reasons. But what are the alternatives, and can they really reduce the use of animals in drug development? Before drug developers let […] September 26, 2025 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 24 Sep 2025 Eli Lilly’s strategy in motion: Beyond diabetes and obesity Delve into a biopharma giant’s strategy, Eli Lilly. This past year, the company secured regulatory milestones and strategic deals. September 24, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 10 Sep 2025 When rare diseases are not so rare after all: A closer look at where and why this happens Discover how in some communities around the world, the prevalence of rare diseases is higher due to factors like cousin marriages. September 10, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email